“…We extracted the following clinical and pathological data from the database: age, sex, body mass index (BMI), American Society of Anesthesiologists performance score, hypertension, diabetes, hepatitis B/C infection, clinical cancer stage according to the tumor-node-metastasis (TNM) Classification of Malignant Tumors (Union for International Cancer Control, 8th edition) [ 28 ], Model for End-Stage Liver Disease (MELD) score [ 29 ], clinical staging according to albumin–bilirubin (ALBI) score [ 30 ] and the Japan Integrated Staging (JIS) score [ 31 ], previous treatment, ascites within 30 days prior to surgery, laboratory values, Child–Pugh grade, indocyanine green (ICG) retention rate, type of resection (i.e., anatomical or non-anatomical), LLR difficulty score in the IWATE criteria [ 32 ], intraoperative data (blood loss, transfusions, and operation time), short-term outcomes (90-day morbidity, major morbidity, complications, and postoperative hospital stay), tumor size and grade, pathologic data [microvascular invasion, capsular invasion, and margin status (i.e., R0 or R1)], and oncological outcomes [recurrence, treatment of recurrence, recurrence-free survival (RFS), and overall survival (OS)]. Informed consent was obtained in accordance with the principles of the Declaration of Helsinki.…”